The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease

被引:0
作者
Leilei Ma
Li Zhang
Jing Li
Xiaotian Zhang
Yiran Xie
Xiaochen Li
Bo Yang
Hongtao Yang
机构
[1] First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Department of Nephrology
[2] National Clinical Research Center for Chinese,undefined
[3] Medicine Acupuncture and Moxibustion,undefined
来源
Molecular Medicine | / 29卷
关键词
Gut microbiota; Microbial metabolites; Mitochondrial; Diabetic kidney disease;
D O I
暂无
中图分类号
学科分类号
摘要
Diabetic kidney disease (DKD), has become the main cause of end-stage renal disease (ESRD) worldwide. Lately, it has been shown that the onset and advancement of DKD are linked to imbalances of gut microbiota and the abnormal generation of microbial metabolites. Similarly, a body of recent evidence revealed that biological alterations of mitochondria ranging from mitochondrial dysfunction and morphology can also exert significant effects on the occurrence of DKD. Based on the prevailing theory of endosymbiosis, it is believed that human mitochondria originated from microorganisms and share comparable biological characteristics with the microbiota found in the gut. Recent research has shown a strong correlation between the gut microbiome and mitochondrial function in the occurrence and development of metabolic disorders. The gut microbiome’s metabolites may play a vital role in this communication. However, the relationship between the gut microbiome and mitochondrial function in the development of DKD is not yet fully understood, and the role of microbial metabolites is still unclear. Recent studies are highlighted in this review to examine the possible mechanism of the gut microbiota-microbial metabolites-mitochondrial axis in the progression of DKD and the new therapeutic approaches for preventing or reducing DKD based on this biological axis in the future.
引用
收藏
相关论文
共 50 条
  • [31] Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in db/db mice
    Yan, Hongjia
    Zhang, Yi
    Lin, Xiaoqian
    Huang, Juan
    Zhang, Fuwei
    Chen, Caiyu
    Ren, Hongmei
    Zheng, Shuo
    Yang, Jian
    Hui, Suocheng
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2024, 75 (03) : 264 - 276
  • [32] Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice
    Wang, Peipei
    Guo, Ruixue
    Bai, Xiwen
    Cui, Wen
    Zhang, Yiding
    Li, Huangmin
    Shang, Jin
    Zhao, Zhanzheng
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [33] Altered gut microbiota and microbial biomarkers associated with chronic kidney disease
    Lun, Hengzhong
    Yang, Weihua
    Zhao, Shuping
    Jiang, Meijie
    Xu, Mingjie
    Liu, Fenfen
    Wang, Yunshan
    MICROBIOLOGYOPEN, 2019, 8 (04):
  • [34] Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies
    Marroncini, Giada
    Naldi, Laura
    Martinelli, Serena
    Amedei, Amedeo
    BIOMEDICINES, 2024, 12 (07)
  • [35] Gut Microbiota Composition and Its Metabolites in Different Stages of Chronic Kidney Disease
    Chen, Tso-Hsiao
    Liu, Chao-Wei
    Ho, Yi-Hsien
    Huang, Chun-Kai
    Hung, Ching-Sheng
    Smith, Barry H.
    Lin, Jung-Chun
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [36] Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota
    Ran, Zhao
    Mu, Ben-Rong
    Wang, Dong-Mei
    Xin-Huang, Quan-Hong
    Ma, Quan-Hong
    Lu, Mei-Hong
    MOLECULAR NEUROBIOLOGY, 2025, 62 (04) : 5273 - 5296
  • [37] Discussion on the treatment of diabetic kidney disease based on the "gut-fat-kidney" axis
    He, Yaping
    Jia, Dengke
    Chen, Wenying
    Liu, Juan
    Liu, Congrong
    Shi, Xiaowei
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, 57 (04) : 1233 - 1243
  • [38] Gut microbiota profiling reflects the renal dysfunction and psychological distress in patients with diabetic kidney disease
    Li, Qi
    Xie, Suyi
    Liu, Yali
    Yue, Wei
    Wang, Limin
    Liang, Yi
    Chen, Yan
    Yuan, Huijuan
    Yu, Jiawei
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [39] Compositional Alterations of Gut Microbiota in Patients with Diabetic Kidney Disease and Type 2 Diabetes Mellitus
    He, Xin
    Sun, Jiping
    Liu, Chao
    Yu, Xiaoyang
    Li, Huixian
    Zhang, Wenjing
    Li, Yan
    Geng, Yingzhou
    Wang, Zhigang
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 755 - 765
  • [40] A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals
    Han, Shisheng
    Chen, Min
    Cheng, Pei
    Zhang, Zeng
    Lu, Yan
    Xu, Yanqiu
    Wang, Yi
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13